Vorinostat in Treating Patients With Kidney Cancer

Part of paid clinical trials in San Antonio, Texas.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00278395
Phase
PHASE2
Status
Completed

Conditions

  • Recurrent Renal Cell Carcinoma
  • Stage IV Renal Cell Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial is studying how well vorinostat works in treating patients with advanced kidney cancer. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking blood flow to the tumor.

Key Dates

Start date
Oct 31, 2005
Status verified
Oct 2017
Primary completion
Feb 28, 2010
Completion
Feb 28, 2010

Study Design

Enrollment
14 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm I
    Patients receive oral vorinostat (SAHA) twice daily on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may have the option of continuing treatment beyond 52 weeks at the discretion of the investigator.

Primary Outcome Measure

Objective Response [ Time Frame: 1 year ]

Locations (2)

FacilityCityStateZIPSite coordinators
Cancer Therapy and Research Center at The UT Health Science Center at San AntonioSan AntonioTexas78229-
Institute for Drug DevelopmentSan AntonioTexas78245-

Find similar trials in San Antonio, TX

By research site
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio· San Antonio, TXInstitute for Drug Development· San Antonio, TX

Related Studies